Abstract: Compositions and methods for enhancing the immune response of a mammal to an antigen by engaging the OX-40 receptor on the surface of T-cells are disclosed, comprising administering to the mammal a composition comprising a purified OX-40 receptor binding agent and a pharmaceutically acceptable carrier, wherein the composition is administered to the mammal such that the OX-40 receptor binding agent is presented to T-cells of the mammal during or shortly after priming of the T-cells by the antigen. Such compositions and methods can be used in immunization and cancer treatment.

Abstract: Compositions and methods for enhancing the immune response of a mammal to an antigen by engaging the OX-40 receptor on the surface of T-cells are disclosed, comprising administering to the mammal a composition comprising a purified antibody that specifically binds the OX-40 receptor and a pharmaceutically acceptable carrier, wherein said composition is administered to the mammal such that the antibody that specifically binds the OX-40 receptor is presented to T-cells of the mammal during or shortly after priming of the T-cells by the antigen. Such compositions and methods can be used in immunization and cancer treatment.

Abstract: It is a general object of the invention to provide a method of effecting tissue repair or replacement using a biomaterial. It is a specific object of the invention to provide a biomaterial suitable for use as a stent, for example, a vascular stent, or as a conduit replacement, as an artery, vein or a ureter replacement. The biomaterial can also be used as a stent or conduit covering or lining. The present invention relates to a method of repairing, replacing or supporting a section of a body tissue. The method comprises positioning a biomaterial at the site of the section and bonding the biomaterial to the site or to the tissue surrounding the site. The bonding is effected by contacting the biomaterial and the site, or tissue surrounding the site, at the point at which said bonding is to be effected, with an energy absorbing agent. The agent is then exposed to an amount of energy absorbable by the agent sufficient to bond the biomaterial to the site or to the tissue surrounding the site.

Abstract: Levels of psoralen concentration in a biological detection target are determined so that an appropriate UVA light dose of PUVA therapy can be delivered to a biological treatment target. The appropriate therapy is determined by the product of the UVA light dose and psoralen concentration level. After determination of a baseline optical autofluoresence signal from the detection target, a first dosage of psoralen (preferably 8-methoxypsoralen ?8-MOP!) is administered. Thereafter, the detection target is irradiated under the same conditions as the pre-psoralen irradiation. Then, the optical return from the psoralen-treated detection target is analyzed. A computer (86) compares the pre-psoralen optical return and psoralen-treated optical return to calculate a real time determination of the concentration level of psoralen in the treatment target.

Abstract: Levels of psoralen concentration in a biological detection target are determined so that an appropriate UVA light dose of PUVA therapy can be delivered to a biological treatment target. The appropriate therapy is determined by the product of the UVA light dose and psoralen concentration level. After determination of a baseline optical autofluoresence signal from the detection target, a first dosage of psoralen (preferably 8-methoxypsoralen [8-MOP]) is administered. Thereafter, the detection target is irradiated under the same conditions as the pre-psoralen irradiation. Then, the optical return from the psoralen-treated detection target is analyzed. A computer (86) compares the pre-psoralen optical return and psoralen-treated optical return to calculate a real time determination of the concentration level of psoralen in the treatment target.